Podcasts about Medical research

Featuring articles on PI3K-altered colorectal cancer, type 2 diabetes, oral semaglutide, and proportional-assist ventilation; a review article on tumor lysis syndrome; a case report of a girl with chest pain and bone and liver lesions; and Perspectives on integrating pharmacotherapy into tobacco control, on Medicaid enrollees with chronic conditions, and on ultraprocessed food.

“Someday, devices that stimulate the vagus nerve may replace many of the drugs people take for chronic disease.”— Dr. Kevin Tracey  Key Resources & Links  Dr. Kevin J. Tracey's new book: The Great Nerve  Dr. Kevin J. Tracey's TedTalk: Watch Here  Center for Bioelectronic Medicine: Official Site  SetPoint Medical: Official Site  Clinical Trials: clinicaltrials.gov  Follow me on Instagram for updates and giveaways: @BarbaraHannahGrufferman  Why Listen to This Episode?  In this first of a two-part series, I sit down with Dr. Kevin J. Tracey, neurosurgeon, CEO of the Feinstein Institutes for Medical Research, and founder of the field of bioelectronic medicine. He's also one of the most widely cited medical experts in the world. Together, we explore the science behind the vagus nerve, a vast communication highway between your brain and body that is proving to be a powerful regulator of inflammation.  Just weeks ago, the FDA approved the first implantable vagus nerve device for rheumatoid arthritis, a breakthrough that could pave the way for treating other conditions without drugs. Dr. Tracey explains what this milestone means, how the device works, and why it could someday replace some of the medications people rely on for chronic disease management.  What You'll Learn in Part 1  What the vagus nerve is, where it's located, and why it matters.  How inflammation drives diseases like heart disease, Alzheimer's, arthritis, and more.  The story behind the FDA-approved device that may change how we treat rheumatoid arthritis.  Why bioelectronic medicine could represent a seismic shift in healthcare.  ENTER TO WIN A COPY OF ‘THE GREAT NERVE'! How to enter: listen to the episode, share the link on Instagram and tag me @BarbaraHannahGrufferman⁠ . You'll be automatically entered to win a copy of this seminal book.   If you're enjoying Age Better, I'd be so grateful if you left a quick review wherever you listen.      And if there's a topic or question you'd love for me to cover in a future episode, send a note to agebetterpodcast@gmail.com -- I love hearing from you!    Learn more about your ad choices. Visit megaphone.fm/adchoices

Send us a textIn this week's Journal Club, Ben and Daphna review several recent neonatal studies with direct implications for practice.They begin with the BORN trial from Italy, which investigated whether transfusing preterm infants with cord blood–derived red blood cells, rather than adult donor blood, could reduce severe retinopathy of prematurity (ROP). While the intention-to-treat analysis showed no difference, per-protocol findings suggest potential benefits that warrant larger trials.Next, they review a large international cohort study of outcomes in infants born at 22–23 weeks, highlighting striking variability in survival and morbidity across networks, with Japan showing the highest survival rates.The EBNeo segment features Dr. Gabriel Altit discussing an Indian randomized trial comparing norepinephrine vs. dopamine as first-line therapy for neonatal septic shock. Although primary outcomes were similar, norepinephrine showed some favorable metabolic and perfusion markers.The hosts then cover a delivery room resuscitation study identifying expiratory tidal volumes of 4–5 ml/kg as key for successful lung aeration, a Canadian trial of atropine for neonatal intubation, and a retrospective study from Alabama on optimal timing and frequency of pulmonary hypertension screening in BPD.The episode concludes with a case report on the use of continuous glucose monitoring in a neonate with congenital hyperinsulinism.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

In this week's episode we'll learn about persistent changes in immune profiles in patients who have had diffuse large B-cell lymphoma, or DLBCL, and other cancers; that plasminogen activation and plasmin activity do not appear to play a role in routine physiological prevention of venous thromboembolism, or VTE; and about a novel mechanism that makes hematological malignancies carrying epigenetic mutations susceptible to PARP inhibitors.Featured Articles:Large B-cell lymphoma imprints a dysfunctional immune phenotype that persists years after treatmentPlasminogen activation and plasmin activity are not required to prevent venous thrombosis/thromboembolismTransposable elements as novel therapeutic targets for PARPi-induced synthetic lethality in PcG-mutated blood cancer

Featuring articles on hypertrophic cardiomyopathy, rehabilitation after myocardial infarction in older adults, the 2024 Marburg virus disease outbreak in Rwanda, and medications for opioid use disorder in county jails; a case report of a woman with dyspnea and fatigue; a Medicine and Society on the race-correction debates; and Perspectives on recent efforts toward equity, on medical research funding in a divided America, and on the end of days.

In this week's episode, we'll learn about how TET2 is often mutated in myeloid malignancies and clonal hematopoiesis. In new work, expansion of Tet2-mutant HSPCs was dependent on Ncoa4, the cargo receptor mediating ferritinophagy. We'll iron out the implications. After that: a double-oh-seven license to kill in T-cell leukemia/lymphoma. WU-CART-007 is an off-the-shelf CAR T product with manageable safety and encouraging efficacy. With further work, it could become a new option for patients in urgent need of therapy. Finally: a comprehensive genetic study of classical Hodgkin lymphoma using circulating tumor DNA. This new research provides novel and complex insights on genetic subtypes, prognostic biomarkers, neoantigens in the disease environment, and more.Featured Articles:An in vivo barcoded CRISPR-Cas9 screen identifies Ncoa4-mediated ferritinophagy as a dependence in Tet2-deficient hematopoiesisPhase 1/2 trial of anti-CD7 allogeneic WU-CART-007 for patients with relapsed/refractory T-cell malignanciesA comprehensive genetic study of classic Hodgkin lymphoma using circulating tumor DNA

Featuring articles on obesity, type 1 diabetes, syphilis, and heparin-induced thrombocytopenia; a review article on the management of acute type B aortic dissection; a Clinical Problem-Solving describing a fruitful workup; and Perspectives on the corporatization deal, on advancing physician-scientist training in China, and on the rise of drug innovation in China.

On this episode of JHLT: The Podcast, the Digital Media Editors invite first author Ahmet Bilgili, from the University of Florida's Congenital Heart Center, and senior author Eric I. Jeng, MD, from the University of Florida's MCS program. Bilgili and Dr. Jeng discuss their paper, “Optimal pretransplant duration with HeartMate III left ventricular assist device: A contemporary analysis.” The discussion explores: Prior gaps in the literature regarding contemporary HM3 outcomes in relation to transplantation—and the study's potential influence on policy Which length of HM3 support influenced better post-transplant outcomes—and which ages were most influenced How these findings might change standard practice For the latest studies from JHLT, visit www.jhltonline.org/current, or, if you're an ISHLT member, access your Journal membership at www.ishlt.org/jhlt. Don't already get the Journal and want to read along? Join the International Society of Heart and Lung Transplantation at www.ishlt.org for a free subscription, or subscribe today at www.jhltonline.org.  

Kevin J. Tracey is president and CEO and the Karches Family Distinguished Chair in Medical Research at the Feinstein Institutes for Medical Research; professor of Molecular Medicine and Neurosurgery at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell; and Executive Vice President, Research, at Northwell Health. A leader in the scientific fields of inflammation and bioelectronic medicine, his contributions include discovery and molecular mapping of neural circuits controlling immunity. Dr. Tracey received his BS in chemistry, summa cum laude, Phi Beta Kappa, from Boston College in 1979, and his MD from Boston University in 1983. He trained in neurosurgery from 1983 to 1992 at the New York Hospital-Cornell University Medical Center and was a guest investigator at the Rockefeller University before moving in 1992 to the Feinstein Institutes. There he directs the Laboratory of Biomedical Science and was appointed president and CEO in 2005.An inventor of more than 120 United States patents and author of more than 400 scientific publications, he cofounded the Global Sepsis Alliance, a non-profit organization supporting the efforts of more than 1 million sepsis caregivers in over 70 countries. Dr. Tracey is the author of Fatal Sequence (Dana Press) and delivers lectures nationally and internationally on inflammation, sepsis, the neuroscience of immunity, and bioelectronic medicine.

A physician dad shares how politics are disrupting research, parenting transgender kids, and the sports debate.In this episode, Diana sits down with her husband, Arthur, a physician researcher and parent, to talk about how today's shifting policies and headlines affect real families. Together, they cover three big themes:The ripple effects of political decisions on medical research and patient careWhat it means for parents of transgender kids to prepare and protect their familiesThe science, myths, and realities behind the transgender sports debateThis candid conversation sheds light on how systemic changes impact everyday lives, and what families and allies can keep in mind moving forward.If you're taking something away from our podcast, we'd appreciate it if you'd take a moment to provide us with a review; the more listeners and reviews, the more people we can reach and support. As always, feel free to reach out to us at transparentlyspeakingpodcast@gmail.com.

In this week's episode we'll learn about targeting NPM1 in acute myeloid leukemia. Researchers report the first clinical evidence of a menin inhibitor inducing complete remissions in AML with a NPM1 mutation. This validates NPM1 as a new therapeutic target in AML, alongside FLT3, IDH1/2, and KMT2A. Also on the podcast: targeting CD137 to prevent graft-versus-host disease. In nonhuman primates, a single dose of a CD137 antibody-drug conjugate provided long-term protection, with one important caveat: the potential for viral reactivation.Featured Articles: Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 studyA single dose of a CD137 antibody–drug conjugate protects rhesus macaque allogeneic HCT recipients against acute GVHD

Blood Editor, Dr. Thomas Coates interviews Dr. Emanuele Angelucci on his paper, "How I manage iron overload in the hematopoietic cell transplantation setting" which is featured in Blood's "How I Treat Series on Iron Overload in Hematologic Disorders". See the full How I Treat series in volume 145 issue 4 of Blood. 

Kevin J. Tracey, MD is president and CEO of the Feinstein Institutes for Medical Research at Northwell Health, a pioneer of vagus nerve research and author of the recent book, The Great Nerve: The New Science of the Vagus Nerve and How to Harness Its Healing Reflexes. This episode is brought to you by:Eight Sleep Pod Cover 5 sleeping solution for dynamic cooling and heating: EightSleep.com/Tim (use code TIM to get $350 off your very own Pod 5 Ultra.)AG1 all-in-one nutritional supplement: https://DrinkAG1.com/Tim (1-year supply of Vitamin D plus 5 free AG1 travel packs with your first subscription purchase.)Wealthfront high-yield cash account: https://Wealthfront.com/Tim (Start earning 4.00% APY on your short-term cash until you're ready to invest. And when new clients open an account today, you can get an extra fifty-dollar bonus with a deposit of five hundred dollars or more.) Terms apply. Tim Ferriss receives cash compensation from Wealthfront Brokerage, LLC for advertising and holds a non-controlling equity interest in the corporate parent of Wealthfront Brokerage. See full disclosures here.Timestamps:00:00 Tim's intro: why he dismissed vagus-nerve hype06:34 What the vagus nerve actually is, plus common myths11:31 Breaking news: FDA approval for SetPoint's RA implant + Kelly Owens's turnaround21:11 Inflammation 101: when healing turns harmful31:37 Bioelectronic medicine: from lab insight to real devices55:26 TNF, IL-1, and IL-6: immune drivers and what VNS modulates56:06 Exercise & recovery: vagal signals, IL-6, and adaptation56:30 Cold exposure & breathwork: sympathetic spike, parasympathetic payoff59:04 Chronic inflammation today: prevalence, diagnostics, and uncertainty59:53 Autoimmunity: genes, environment, infections01:01:08 Stress hormones, personality traits, and metabolic fallout01:05:41 VNS tech landscape: implants, focused ultrasound, and what's just TENS01:11:14 Ear maps, revisited: the real science behind auricular stimulation01:27:52 Ulf Andersson: auricular TENS, famotidine, and a depression turnaround01:36:48 Depression & inflammation: where VNS helps (and where it doesn't)01:41:38 Body-brain loop: how inflammation signals ride the vagus nerve01:42:56 Why VNS can lift mood: a working theory01:43:22 Ulf's setup: electrode placement and twice-daily routine01:44:37 Acupuncture, fertility, and plausible vagal links01:47:23 Chronic pain through an inflammation lens01:48:34 Neural “engrams”: how the brain can store inflammatory memories02:02:35 Cervical TENS vs. true VNS: mechanisms and open questions02:12:15 On stage with the Dalai Lama: blue energy and two vagus nerves02:16:55 Closing thoughts: self-care vs. medical devices, and what's next*For show notes and past guests on The Tim Ferriss Show, please visit tim.blog/podcast.For deals from sponsors of The Tim Ferriss Show, please visit tim.blog/podcast-sponsorsSign up for Tim's email newsletter (5-Bullet Friday) at tim.blog/friday.For transcripts of episodes, go to tim.blog/transcripts.Discover Tim's books: tim.blog/books.Follow Tim:Twitter: twitter.com/tferriss Instagram: instagram.com/timferrissYouTube: youtube.com/timferrissFacebook: facebook.com/timferriss LinkedIn: linkedin.com/in/timferrissPast guests on The Tim Ferriss Show include Jerry Seinfeld, Hugh Jackman, Dr. Jane Goodall, LeBron James, Kevin Hart, Doris Kearns Goodwin, Jamie Foxx, Matthew McConaughey, Esther Perel, Elizabeth Gilbert, Terry Crews, Sia, Yuval Noah Harari, Malcolm Gladwell, Madeleine Albright, Cheryl Strayed, Jim Collins, Mary Karr, Maria Popova, Sam Harris, Michael Phelps, Bob Iger, Edward Norton, Arnold Schwarzenegger, Neil Strauss, Ken Burns, Maria Sharapova, Marc Andreessen, Neil Gaiman, Neil de Grasse Tyson, Jocko Willink, Daniel Ek, Kelly Slater, Dr. Peter Attia, Seth Godin, Howard Marks, Dr. Brené Brown, Eric Schmidt, Michael Lewis, Joe Gebbia, Michael Pollan, Dr. Jordan Peterson, Vince Vaughn, Brian Koppelman, Ramit Sethi, Dax Shepard, Tony Robbins, Jim Dethmer, Dan Harris, Ray Dalio, Naval Ravikant, Vitalik Buterin, Elizabeth Lesser, Amanda Palmer, Katie Haun, Sir Richard Branson, Chuck Palahniuk, Arianna Huffington, Reid Hoffman, Bill Burr, Whitney Cummings, Rick Rubin, Dr. Vivek Murthy, Darren Aronofsky, Margaret Atwood, Mark Zuckerberg, Peter Thiel, Dr. Gabor Maté, Anne Lamott, Sarah Silverman, Dr. Andrew Huberman, and many more.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

First, The Indian Express' Diplomatic Affairs Editor Shubhajit Roy breaks down what the recent visit of Chinese Foreign Minister Wang Yi signals about evolving India–China ties, the friction and convergence in forums like BRICS and SCO.Next, we talk to The Indian Express' Anonna Dutt on how the Indian Council of Medical Research is expanding wastewater surveillance to track outbreaks of diseases and how this public health tool could provide early warning signals in 50 cities across India. (16:25)And finally, we turn to rural Haryana, where The Indian Express' Sukhbir Siwach explains a rare Supreme Court-supervised recount has reversed the outcome of a 2022 sarpanch election. (26:13)Hosted by Ichha SharmaProduced and written by Shashank Bhargava, Niharika Nanda and Ichha SharmaEdited and mixed by Suresh Pawar

Ontario Premier Doug Ford says he'll crack down on labs using cats and dogs in experiments after revelations that beagles were subjected to heart attack studies at St. Joseph's Health Care in London, Ontario. The case has ignited debate over the role of animals in science. We hear from animal bioethicist Andrew Fenton, Western University researcher Arthur Brown, and Executive Director of the Canadian Centre for Alternatives to Animal Methods, Charu Chandrasekera, who advocates for replacing animal testing with new technologies.

In this week's episode we'll learn about how by combining PET response with circulating tumor DNA, or  ctDNA, in newly treated patients with follicular lymphoma, investigators identify those patients likely to progress within 24 months of initial treatment, also known as POD24. After that: Immune hotspots in aplastic anemia. These newly identified hotspots potentially represent sites in the bone marrow where the active immune response takes place, driving the destruction of hematopoietic stem and progenitor cells. Finally, allogeneic transplantation for Hodgkin lymphoma in the checkpoint inhibitor era. In a large, retrospective study, patients with prior checkpoint inhibitor exposure had remarkable outcomes, particularly when post-transplant cyclophosphamide was used.Featured Articles: Combined PET and ctDNA response as predictors of POD24 for follicular lymphoma after first-line induction treatmentImaging Mass Cytometry Reveals the Order of Events in the Pathogenesis of Immune-Mediated Aplastic AnemiaOutcomes of Allogeneic HCT in Hodgkin Lymphoma in the Era of Checkpoint Inhibitors: A Joint CIBMTR and EBMT Analysis

This is our last show from Ireland for a while. We've had some very special houseguests, including our friends Alan and Lisa Robertson from Duck Dynasty and the Unashamed Podcast. They had a great time seeing the sights with us—watch the podcast to see our journey to a very interesting pub.Also on today's show, we reveal how the “nice people” in society are declaring YOU unfit for existence, from the womb to old age. We bring you a chilling interview exposing the questionable science and moral vacuum in the gold rush for designer babies.And watch the show to learn about the horrific expansions of Canada's assisted suicide law. You won't believe how common it has become and how much of America is heading down the same path.The New Yorker magazine—home of great writing and writers—has a racist on its staff. But don't worry—she's the fashionable kind. She only hates white people, so the left has no problem with that.We also have an exclusive story this week as we uncover the great veteran disability scam and how America's love affair with its military is allowing bad actors to rob us blind. Listen as the financial Jerry Springer exposes a veterans' scandal while trying to pound sense into some Gen Z deadbeats.Leave a comment wherever you get our content—you never know, we may read it on the show!Remember, we are a 501(c)(3) nonprofit. Please visit our website, unreportedstorysociety.com, and give what you can so we can keep bringing you our show and special projects. Your donation is tax-deductible.Click here to donate to the Unreported Story Society: ⁠https://unreportedstorysociety.com/⁠Did you know you don't have to wait a week to get the scoop? Subscribe to our Stories.io Substack for news and views every day.Click here to read Phelim's story on the abuse of VA disability benefits: https://phelimmcaleer.substack.com/p/exposing-the-great-veteran-disability?utm_campaign=email-half-post&r=58t52b&utm_source=substack&utm_medium=emailSubstack link: https://phelimmcaleer.substack.com/

Featuring articles on lung cancer, vasomotor symptoms in breast cancer, autoimmune pulmonary alveolar proteinosis, and high-risk cutaneous squamous-cell carcinoma; a review article on educational strategies for clinical supervision of AI use; a case report of a woman with fatigue and myalgias; a Sounding Board on vaccine policy in the U.S.; and Perspectives on preventive care at the Supreme Court, regulating private equity in health care, reforming the prescription drug user fee program, and on the consultant.

On this episode of JHLT: The Podcast, the Digital Media Editors invite first author Luke Williams, a cardiothoracic surgery trainee at Royal Papworth Hospital, NHS Blood and Transplant Clinical Research Fellow, and a PhD student at Cambridge University in the UK. Luke discusses his paper, “The United Kingdom's experience of controlled donation after circulatory death direct procurement of lungs with concomitant abdominal normothermic regional perfusion with an analysis of short-term outcomes.”   The discussion explores: Requirements, regulations, and practices in the UK around DCD procurement and A-NRP How survival rates differ and what they might imply about primary graft dysfunction in DCD versus DBD Further work planned in the area in the UK and throughout Europe For the latest studies from JHLT, visit www.jhltonline.org/current, or, if you're an ISHLT member, access your Journal membership at www.ishlt.org/jhlt.   Don't already get the Journal and want to read along? Join the International Society of Heart and Lung Transplantation at www.ishlt.org for a free subscription, or subscribe today at www.jhltonline.org.  

In this week's episode, we'll learn more about how exogenous CD19 stimulation affects CAR T-cell persistence in B-cell acute lymphoblastic leukemia treated with CD19 CAR T-cell therapy; new algorithms that incorporate sequential rapid immune-assays, intended to improve diagnosis of heparin-induced thrombocytopenia, and resource-adaptive survival prediction models to help guide management of patients with chronic myelomonocytic leukemia.Featured Articles:Outcomes of PLAT-02 and PLAT-03: evaluating CD19 CAR T-cell therapy and CD19-expressing T-APC support in pediatric B-ALLSequential combinations of rapid immunoassays for prompt recognition of heparin-induced thrombocytopeniaBLAST: a globally applicable and molecularly versatile survival model for chronic myelomonocytic leukemia

Daniel Blumenthal, VP of Strategy at MDClone, is building synthetic data models to mimic real patient data without the need to protect the identity of individuals. This type of data is being utilized in drug discovery and development, building predictive tools and new care models, and to better understand biases in clinical trials making them more representative. AI tools play an essential role in generating and validating synthetic data as well as integrating it into various processes and environments. Daniel explains, "Synthetic data means different things to different people. So I definitely would want to start with sharing what it usually means to MDClone, which is creating data based on real populations of patients, real patient data. Learning from that real patient data, extracting essentially the statistics from that data, understanding the relevant patterns that exist inside that data, and then, based on the statistics alone, generating a brand-new set of data, a brand-new set of people, and the synthetic data that we generate."   "If you look at it, essentially with your naked eye, you wouldn't know it's not real people. It has the same structure, has the same content appearance, and yet, inside, synthetic data contains no real people. So very different from other approaches to protecting patient privacy, which take a patient data set and hash data, mask data, or remove information like IDs, names, or locations."  "Instead of taking that sort of approach, synthetic data actually generates a brand-new set of people, fake people, that in our case, as we build it, maintain the same statistical properties, such that any analysis you want to complete, you could accomplish using the synthetic dataset just as you would with the original dataset. That it will yield the same meaningful conclusions as the synthetic that it would with the original." #MDClone #MedAI #AI #SyntheticData #DrugDevelopment #DrugDiscovery #ClinicalTrials #PatientPrivacy mdclone.com Download the transcript here

Daniel Blumenthal, VP of Strategy at MDClone, is building synthetic data models to mimic real patient data without the need to protect the identity of individuals. This type of data is being utilized in drug discovery and development, building predictive tools and new care models, and to better understand biases in clinical trials making them more representative. AI tools play an essential role in generating and validating synthetic data as well as integrating it into various processes and environments. Daniel explains, "Synthetic data means different things to different people. So I definitely would want to start with sharing what it usually means to MDClone, which is creating data based on real populations of patients, real patient data. Learning from that real patient data, extracting essentially the statistics from that data, understanding the relevant patterns that exist inside that data, and then, based on the statistics alone, generating a brand-new set of data, a brand-new set of people, and the synthetic data that we generate."   "If you look at it, essentially with your naked eye, you wouldn't know it's not real people. It has the same structure, has the same content appearance, and yet, inside, synthetic data contains no real people. So very different from other approaches to protecting patient privacy, which take a patient data set and hash data, mask data, or remove information like IDs, names, or locations."  "Instead of taking that sort of approach, synthetic data actually generates a brand-new set of people, fake people, that in our case, as we build it, maintain the same statistical properties, such that any analysis you want to complete, you could accomplish using the synthetic dataset just as you would with the original dataset. That it will yield the same meaningful conclusions as the synthetic that it would with the original." #MDClone #MedAI #AI #SyntheticData #DrugDevelopment #DrugDiscovery #ClinicalTrials #PatientPrivacy mdclone.com Listen to the podcast here

In this episode, Associate Blood editor Dr. Selina Luger leads a discussion with Drs. Courtney DiNardo, Eunice Wang, Andrew Wei and Gail Roboz about the advances in treatment options for Acute Myeloid Leukemia (AML). See the full How I Treat series on Acute Myeloid Leukemia in volume 145 issue 12 of Blood journal.

Featuring articles on overweight, obesity and diabetes; lactated Ringer's solution versus normal saline; and spinal muscular atrophy; a review article on metabolic dysfunction–associated steatotic liver disease; a case report of a woman with respiratory failure and abnormal chest imaging; and Perspectives on dismantling public health infrastructure, on progress lost, on private law in American health care, and on the serendipitous dance between life and death.

Dr. Kevin J. Tracey, President and CEO of the Feinstein Institutes for Medical Research joins the podcasts to share his insights on the groundbreaking role of the vagus nerve in regulating inflammation and its implications for autoimmune diseases like rheumatoid arthritis. Dr. Tracey explains how inflammation, while essential for healing, becomes problematic when uncontrolled—leading to chronic conditions. He introduces the concept of the “inflammatory reflex,” a neural pathway through the vagus nerve that can be harnessed to modulate immune responses. The episode highlights the FDA-approved SetPoint Therapy System, a non-drug, implantable vagus nerve stimulator that offers targeted relief without immunosuppression. Dr. Tracey discusses its clinical success, safety profile, and future applications in conditions such as multiple sclerosis, PTSD, and stroke rehabilitation. The conversation emphasizes the promise of bioelectronic medicine in transforming treatment paradigms for chronic inflammatory diseases. In the podcast interview, Dr. Kevin J. Tracey disclosed that he is a co-founder of SetPoint Medical, the company behind the FDA-approved vagus nerve stimulation device for rheumatoid arthritis 1. He also stated that he serves as a consultant to the company, assisting with its development and research initiatives 1. While he clarified that he is not privy to all future plans of the company, his dual role as both a researcher and company consultant is a relevant professional disclosure for listeners, especially those considering the therapy discussed. Find out more here: Personal Twitter: https://x.com/KevinJTraceyMD Personal Linkedin: https://www.linkedin.com/in/kevinjtraceymd/ Feinstein Institutes: https://www.linkedin.com/company/the-feinstein-institutes-for-medical-research Company website: https://feinstein.northwell.edu/ Dr. Tracey's research profile: https://feinstein.northwell.edu/institutes-researchers/our-researchers/kevin-j-tracey-md Center for Bioelectronic Medicine website: https://www.northwell.edu/center-for-bioelectronic-medicine The Great Nerve (Amazon): https://a.co/d/7UbRR6C

It's a mystery that has long puzzled researchers. Freud called the phenomenon infantile amnesia, and for many years scientists have wondered whether it's a result of failure to create memories or just a failure to retrieve them. In this episode from March 2025, Ian Sample speaks to Nick Turk-Browne, a professor of psychology at Yale University, whose research appears to point to an answer. Help support our independent journalism at theguardian.com/sciencepod

In this week's episode, we'll learn more about the effects of daratumumab maintenance on minimal residual disease in patients with newly diagnosed, transplant-eligible multiple myeloma; the role of neutrophils in the pathophysiology of myeloproliferative neoplasms; and a genome-wide association study that identified novel genetic loci associated with the risk of heavy menstrual bleeding.Featured ArticlesDaratumumab-bortezomib-thalidomide-dexamethasone for newly diagnosed myeloma: CASSIOPEIA minimal residual disease resultsDefective neutrophil clearance in JAK2^V617F myeloproliferative neoplasms drives myelofibrosis via immune checkpoint CD24Genome-wide meta-analysis of heavy menstrual bleeding reveals 36 risk loci

Featuring articles on treatments for chronic kidney disease and type 2 diabetes, bubonic plague, and advanced breast cancer; a review article on hypogonadism; a Clinical Problem-Solving describing gasping for strength; a Medicine and Society on the infant mortality rate; and Perspectives on profit-driven medicine, on lead contamination in Milwaukee schools, on training health communicators, and on ER and becoming a physician.

On this episode of JHLT: The Podcast, the Digital Media Editors invite first author Gaurav Sharma, PhD, MBA, from the University of Texas Southwestern Medical Center in Dallas. Dr. Sharma discusses his paper, “Metabolic and transcriptomic insights into temperature controlled hypothermic preservation of human donor hearts.” The discussion explores: How donor hearts not offered or declined for transplantation responded in hypothermic preservation versus conventional static cold storage Potentially beneficial genetic signatures yielded by TCHP versus cold storage The surprising response of energy stores in the hearts to the different storage environments How multi-omic approaches could be applied to other organs For the latest studies from JHLT, visit www.jhltonline.org/current, or, if you're an ISHLT member, access your Journal membership at www.ishlt.org/jhlt. Don't already get the Journal and want to read along? Join the International Society of Heart and Lung Transplantation at www.ishlt.org for a free subscription, or subscribe today at www.jhltonline.org.

Sweet poison? New doubts cast over safety of erythritol; Is Greek yogurt a good way to enhance protein intake? Comparing whey, soy, and pea protein isolates; When taking supplements, is it advisable to take periodic breaks to enhance their effectiveness? Tommy John surgery pioneer and longtime Mets medical director dies at 68; Ivermectin, once branded useless “horse paste,” may prove a new weapon against malaria; New findings challenge notion that humans and apes share 99% of their DNA.

Henrietta Lacks was the first human being that we know of to get close enough to 'immortality' to touch it. She died more than 50 years ago but her cells live on.'HeLa' cells were the first human cells to be grown for research, and have been vital in medical advances since the 1950s.But what fascinated science major Rebecca Skloot the most about these cells, was how little was known about the woman behind the name.So she set out to discover who Henrietta Lacks really was.Further informationFirst broadcast in July, 2010.The Immortal Life of Henrietta Lacks is published by Picador.Rebecca's book was turned into a film starring Oprah Winfrey.You can learn more about Henrietta online.You can also hear Richard's full conversation with Helen Macdonald on the ABC Listen App or wherever you get your podcasts. You can also read all about the Conversations origin story on the ABC News website.This episode of Conversations explores science, science communication, weird science, female scientists, modern history, medicine, medical history, medical research, cells, cancer, curing disease.

In the third episode of our five part series in association with Mobile Creches, we bring to you a conversation about the reforms that are needed in order to make the Right to care a universal right.In this conversation, Niharika Nanda is joined by Dr. Soumya Swaminathan, the Principal Adviser at the Union Ministry of Health and Family Welfare for the National Tuberculosis Elimination Program. She was the Former Director General of Indian Council of Medical Research and a Chief Scientist at WHO. She is also the chair of the M.S. Swaminathan Research Foundation.Dr. Soumya shares how we need to provide care and holistic development to children during the age of 0-6 years to provide a foundation for better emotional and physical growth that in the long-term makes them better contributors to economic growth.Hosted and produced by Niharika NandaEdited and mixed by Suresh PawarLinks for previous episodes:Episode 1Episode 2

In this week's episode we'll learn more about enhanced transplant characteristics; targeting the JAK-STAT pathway with ruxolitinib in patients with adult-onset Still's disease and macrophage activation syndrome; and a pair of trials demonstrating lack of benefit for the anti-CD47 monoclonal antibody magrolimab in newly diagnosed acute myeloid leukemia.Featured ArticlesHeterogeneity of high-potency multilineage hematopoietic stem cells and identification of “Super” transplantabilityRuxolitinib targets JAK-STAT signaling to modulate neutrophil activation in refractory macrophage activation syndromeMagrolimab plus azacitidine vs physician's choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 studyThe ENHANCE-3 study: venetoclax and azacitidine plus magrolimab or placebo for untreated AML unfit for intensive therapy

Featuring articles on myeloma, mitochondrial DNA disease, cardiac surgery, and squamous-cell carcinoma; a review article on motor vehicle crash prevention; a case report of a woman with seizure-like activity and odd behaviors; a Medicine and Society article on the evaluation of occupational pulmonary impairment; and Perspectives on Covid-19 vaccines, on public policies, and on living on the edge of the valley of the sick.

In 2024, the Oxford English Dictionary announced its word of the year was ‘brain rot'. The term relates to the supposedly negative effects of consuming social media content, but it struck a chord more widely with many who feel they don't have the mental capacity they once had. Gloria Mark, a professor of informatics at the University of California, Irvine, has been studying our waning attention spans for 20 years. In this episode from January 2025, she tells Madeleine Finlay why she believes our powers of concentration are not beyond rescue, and reveals her top tips for finding focus. Help support our independent journalism at theguardian.com/sciencepod

Send us a textThe Kim B. Davis Show featuring Dr. Angela Celeste May, a clinical, organizational, and forensically trained psychologist, President and Co-founder of A.M. May and Associates, Inc., President and founder of Celeste Productions, Inc., Author, Editor, former columnist, Musician, and 2023 President's Distinction Award winner from the Michigan Psychological Association Foundation discusses, America's Obsession/Entitlement with Black Bodies. We talk about Adriana Smith, a brain dead woman who gave birth to a baby boy named Chance who is in NICU and we examine J. Marion Sims, the father of gynecology and the story of Henrietta Lacks whose cells were kept alive and used without her family's knowledge. The story continues on join in on the conversation.The Kim B. Davis Show is a conversational platform that engages issues around mental health, well-being, and political engagement. You can also email me at Kimberly@kimberlybatchelordavis.comSupport the showThank you for tuning in to the Kim B. Davis Show. You can visit KimBDavis.com to learn more about me as an author and you can find me on FaceBook, Instagram, Twitter, Snapchat, TikTok, and LinkedIn. You can see this show on YouTube.com/KimberlyBatchelorDavis. Thank you again for your support and always remember, Be Magnificent.

Scientists are beginning to understand that ageing is not a simply linear process. Instead, recent research appears to show that we age in three accelerated bursts; at about 40, 60 and 80 years old. To find out what might be going on, Ian Sample hears from Prof Michael Snyder, the director of the Center for Genomics and Personalised Medicine at Stanford University School of Medicine, who explains what the drivers of these bursts of ageing could be, and how they might be counteracted. Help support our independent journalism at theguardian.com/sciencepod

In this week's episode, we'll learn about a JAK inhibitor to prevent complications of CD19-directed CAR T-cell therapy. In a phase 2 study, itacitinib was well tolerated and demonstrated promising reductions in the incidence of cytokine release syndrome and neurotoxicity. After that: investigators report direct interactions between ChAdOx1 and platelets under arterial shear conditions. Investigators say it's a novel biophysical mechanism that potentially contributes to post-vaccination arterial thrombosis. Finally, we explore lineage switch, an emerging form of acute leukemia relapse with dismal outcomes. It arises rapidly following antigen-targeted immunotherapy, highlighting the importance of advanced methods for detection and treatment.Featured Articles: Itacitinib for the prevention of IEC therapy–associated CRS: results from the 2-part phase 2 INCB 39110-211 studyShear-dependent platelet aggregation by ChAdOx1 nCoV-19 vaccine: a novel biophysical mechanism for arterial thrombosisProject EVOLVE: an international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia

Featuring articles on type 2 diabetes, gastric cancer, lung cancer, and malaria; a review article on competency-based medical education; a case report of a man with cough, dyspnea, and hypoxemia; and Perspectives on brain death in pregnancy, on the Supreme Court's failure to protect trans minors, on real-world data, and on avocado and salt.

Matt Dun left school at 17 to join the Australian navy as a submariner and later finished his high school certificate as an adult attending TAFE at night.He then trained in biomedical science and was researching childhood leukaemia when his family received some devastating news, their little daughter Josie was diagnosed with terminal brain cancer.Matt turned all his energy and expertise into searching for treatments to help Josie and other children like her.He found running was one thing that helped him cope with the stress and pain of his daughter's illness, and with his wife founded the charity, RUN DIPGFurther informationThe charity founded by Matt and Phoebe Dun is RUN DIPGFind out more about the Conversations Live National Tour on the ABC website.This episode of Conversations was produced by Jen Leake, executive producer is Nicola Harrison.It explores childhood brain cancer, biomedical science, grief, family, DIPG, drug trials, research, submarines, the Australian Navy, running.

In this episode, Jessica Levinson unpacks the major legal clash between Harvard University and the Trump administration over a $2.6 billion freeze on federal research funding that impacts vital medical studies. Harvard argues the cuts violate its First Amendment rights and the Administrative Procedures Act, claiming they're being punished for not complying with federal demands related to antisemitism policies. The Trump administration insists it's merely a contract dispute, asserting their right to cut funding if Harvard doesn't align with federal priorities. Jessica highlights that the judge in the case seems skeptical of the Trump administration's stance and notes that the outcome could have sweeping effects on academic freedom and federal funding for universities across the country.Here are three key takeaways you don't want to miss:The Legal Battle Over Federal Funding and Academic Freedom: The episode centers on the case of Harvard University vs. the Trump administration over a $2.6 billion freeze in federal research funding to Harvard. Jessica Levinson explains that this legal clash is significant because it questions the extent of federal power over universities and touches on core issues of academic independence and freedom.Harvard's Arguments: First Amendment and Administrative Procedures Act: Harvard argues that the funding freeze violates its First Amendment rights—claiming it's being punished for not complying with federal demands that affect speech and institutional governance. Additionally, Harvard contends the Trump administration failed to follow the correct legal processes outlined in the Administrative Procedures Act, making the funding cuts arbitrary and lacking proper justification.The Trump Administration's Position and Judicial Skepticism: The Trump administration frames the dispute as a simple breach-of-contract issue, saying grant contracts allow for cancellation when an institution's actions don't align with federal priorities. In court, however, the judge sounded skeptical of the administration's position, questioning whether the funding cut was improperly suppressing speech and whether there was enough evidence to justify such a drastic move.Follow Our Host: @LevinsonJessica

Doctors in the UK have announced the birth of eight healthy babies after performing a groundbreaking procedure that creates IVF embryos with DNA from three people. Ian Sample tells Madeleine Finlay about the life-threatening genetic disorders that the technique appears to prevent, and Prof Sir Doug Turnbull describes the 25-year journey to achieving the breakthrough. Help support our independent journalism at theguardian.com/sciencepod

The University of Utah could lose more than $100 million in medical research grants. It poses an "existential threat" to the university's research mission. Holly and Greg discuss what this means for higher education in Utah, and one of the state's premier medical organizations. 

In this week's episode we'll learn more about the use of ruxolitinib plus dexamethasone to treat newly diagnosed patients with adult hemophagocytic lymphohistiocytosis; lysine-specific demethylase-1 inhibitors as a potential new class of therapies for sickle cell disease and other beta-globinopathies; and insights into clinical characteristics of patients with von Willebrand factor levels that are lower than normal but higher than those typically used to diagnose von Willebrand disease.Featured Articles:Ruxolitinib combined with dexamethasone for adult patients with newly diagnosed hemophagocytic lymphohistiocytosis in ChinaNovel, potent, and orally bioavailable LSD1 inhibitors induce fetal hemoglobin synthesis in a sickle cell disease mouse modelClinical phenotype and pathophysiological mechanisms underlying qualitative low VWF

Madeleine Finlay is joined by Ian Sample to discuss three intriguing science and environment stories. From a breakthrough in the quest to create organs in the lab to a world-first climate visa that will see citizens relocate from the island of Tuvalu to Australia, plus what happens when two massive black holes collide. Help support our independent journalism at theguardian.com/sciencepod

Featuring articles on gastric and gastroesophageal junction cancer, pulmonary sarcoidosis, graft-versus-host disease, gastroenteritis in children, the rapid recovery of donor hearts after circulatory death, and an on-table reanimation of a pediatric heart from donation after circulatory death; a review article on fragile X disorders; a case report of a woman with neck swelling and dysphagia; and Perspectives on vaccine policy, on new mammography tools, and on the second life of Jacqui B.

Featuring articles on mild asthma, cardiovascular risk factors, stroke, advanced breast cancer, and transforming health care; a review article on juvenile idiopathic arthritis; a case report of a man with headache and ataxia; and Perspectives on who will care for America, on hospital financial assistance policies, and on libraries burned, and a life lived.

Victoria Jackson is a beauty industry pioneer whose billion-dollar brand helped define the “no-makeup makeup” movement — but her most powerful pivot came far beyond the world of cosmetics. In this episode, Victoria shares how building her business from her garage was just the beginning of a life shaped by resilience, reinvention, and purpose. When her daughter was diagnosed with a rare and life-threatening disease, Victoria left her company behind and stepped into the unknown, founding the Guthy-Jackson Charitable Foundation and ultimately funding groundbreaking medical research that led to the first FDA-approved treatments. Now at 70, she’s returning to beauty with a renewed mission and product line, reimagining beauty for women who, like her, are still evolving. Be sure to subscribe, leave us a rating, and share with your friends if you liked this episode! She Pivots was created by host Emily Tisch Sussman to highlight women, their stories, and how their pivot became their success. To learn more about Victoria, follow us on Instagram @ShePivotsThePodcast or visit shepivotsthepodcast.com. Support the show: https://www.shepivotsthepodcast.com/See omnystudio.com/listener for privacy information.

In this episode of the Bill Press Pod, Bill discusses the alarming cuts to medical and scientific research imposed by the Trump administration. Over 1,300 NIH research grants and over 150 clinical trials, including those on critical diseases like HIV, cancer, and chronic diseases, have been canceled or delayed. Colette Delawalla, founder of Stand Up for Science, talks about the detrimental impact of these cuts on the U.S.'s global leadership in science and the brain drain of scientists to other countries. Additionally, data reporter Irena Hwang from The New York Times provides insight into the extent and reasons behind these cuts, revealing that keywords linked to DEI initiatives were a significant factor in the grant cancellations. The episode highlights the far-reaching consequences for public health and scientific progress. Gift Link to the New York Times article: bit.ly/44pTQk6Today Bill highlights the work of Collette Delawalla's Stand up for Science organization. More information at StandupforScience.net.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In medicine, failure can be catastrophic. It can also produce discoveries that save millions of lives. Tales from the front line, the lab, and the I.T. department. SOURCES:Amy Edmondson, professor of leadership management at Harvard Business School.Carole Hemmelgarn, co-founder of Patients for Patient Safety U.S. and director of the Clinical Quality, Safety & Leadership Master's program at Georgetown University.Gary Klein, cognitive psychologist and pioneer in the field of naturalistic decision making.Robert Langer, institute professor and head of the Langer Lab at the Massachusetts Institute of Technology.John Van Reenen, professor at the London School of Economics. RESOURCES:Right Kind of Wrong: The Science of Failing Well, by Amy Edmondson (2023).“Reconsidering the Application of Systems Thinking in Healthcare: The RaDonda Vaught Case,” by Connor Lusk, Elise DeForest, Gabriel Segarra, David M. Neyens, James H. Abernathy III, and Ken Catchpole (British Journal of Anaesthesia, 2022)."Estimates of preventable hospital deaths are too high, new study shows," by Bill Hathaway (Yale News, 2020).“Dispelling the Myth That Organizations Learn From Failure,” by Jeffrey Ray (SSRN, 2016).“A New, Evidence-Based Estimate of Patient Harms Associated With Hospital Care,” by John T. James (Journal of Patient Safety, 2013).To Err is Human: Building a Safer Health System, by the National Academy of Sciences (1999).“Polymers for the Sustained Release of Proteins and Other Macromolecules,” by Robert Langer and Judah Folkman (Nature, 1976).The Innovation and Diffusion Podcast, by John Van Reenen and Ruveyda Gozen. EXTRAS:"The Curious, Brilliant, Vanishing Mr. Feynman," series by Freakonomics Radio (2024).“Will a Covid-19 Vaccine Change the Future of Medical Research?” by Freakonomics Radio (2020).“Bad Medicine, Part 3: Death by Diagnosis,” by Freakonomics Radio (2016).